{
  "study_id": "NCT05351541",
  "agent": "baseline",
  "run": 1,
  "p_primary_hypothesis_supported": 0.84,
  "effect_direction": "favours intervention",
  "effect_size_90pct_interval": {"low": 3, "high": 20, "metric": "Mean change in BPI interference, 0-70 scale, baseline to 1 month (positive = reduction)"},
  "moderator_prediction": "Placebo add-on (and modafinil) arms show larger reductions than zolpidem-containing arms, because zolpidem's sedative and amnestic effects likely blunt encoding and recall of the psychedelic experience; with ~7 per arm, differences will not be significant.",
  "claim_ids_used": [],
  "rationale": "Hypothesis is pooled within-subject pre-post change with every participant receiving psilocybin plus preparation and integration therapy; no untreated control. Primer: single-arm pre-post self-report symptom outcomes almost always improve significantly (regression to the mean, expectancy, unblinded psychedelic). Participants are treatment-refractory chronic low back pain patients enrolled when motivated; BPI interference is self-report and mood-sensitive. With n~30 and plausible within-subject d of 0.6-1.0, power is high. Risks: dose range down to 1 mg in some participants, amnestic zolpidem arms diluting effect, dropout, chronic-pain outcomes responding less, or a report focusing on arm comparisons. Expect ~8-12 point mean reduction from a baseline near 30-40."
}